ACT015 (Exclusion Criteria)

Exclusion Criteria:

Patients are excluded from participation in the EAP if any of the following exclusion criteria are fulfilled:

1. Major surgery within 14 days (2 weeks) prior to C1D1.
2. Investigational agent (via clinical trial) or anticancer therapy within 5 half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO-292 unless considered by the Investigator to be safe, within the best interest of the patient and with prior Sponsor approval.
3. Radiotherapy for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow, which must be completed at least 4 weeks prior to the first dose of study treatment.
4. CNS surgery or radiation surgery performed within 28 days of the first treatment, within 14 days if stereotactic radiosurgery [SRS]. In patients with symptomatic and/or progressive CNS disease or large CNS tumor burden or leptomeningeal disease, consideration should be given to local treatment (e.g., surgery, radiation) prior to initiation of LOXO-292 therapy if clinically indicated.
5. Clinically significant active cardiovascular disease (including New York Heart Association [NYHA] class III/IV heart failure, stroke, severe valvular disease or uncontrolled hypertension defined as ≥ 140/80 sustained over multiple readings) or history of myocardial infarction within 6 months prior to C1D1; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval > 470 msec. Patients who meet this criteria may be enrolled (with a modified dosing strategy) if clinical rationale exists which is reviewed and agreed upon by the Sponsor.
6. Active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment. Screening for chronic conditions is not required.
7. Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
8. Pregnancy or lactation.
9. Uncontrolled symptomatic hyperthyroidism or hypothyroidism (i.e., the patient required a modification to current thyroid medication within 7 days prior to the first dose).
10. Uncontrolled symptomatic hypercalcemia or hypocalcemia.
11. Current treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (refer to Section 1.6.1).
12. Known hypersensitivity to any of the components of the investigational agent, LOXO-292 or Ora-Sweet® SF and OraPlus®, for patients who will receive LOXO-292

suspension.

13. Current treatment with PPIs. Note: Treatment with PPIs must be stopped 1 or more weeks prior to the first dose of LOXO-292.

14. Any unresolved toxicities from prior therapy greater than the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy. If sufficient clinical rationale exists for treatment despite an unresolved toxicity of a higher Grade, this criterion may be waived with prior Sponsor approval.